MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Bought by Privium Fund Management B.V.

Privium Fund Management B.V. grew its holdings in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 225,078 shares of the company’s stock after purchasing an additional 11,118 shares during the quarter. Privium Fund Management B.V.’s holdings in MeiraGTx were worth $1,371,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Royce & Associates LP raised its stake in MeiraGTx by 5.3% during the 3rd quarter. Royce & Associates LP now owns 795,392 shares of the company’s stock valued at $3,317,000 after acquiring an additional 40,000 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of MeiraGTx by 142.5% during the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock valued at $39,000 after purchasing an additional 5,476 shares during the period. Knoll Capital Management LLC acquired a new position in shares of MeiraGTx during the third quarter valued at $5,212,000. Erste Asset Management GmbH bought a new stake in shares of MeiraGTx during the third quarter valued at about $2,795,000. Finally, Garden State Investment Advisory Services LLC acquired a new stake in MeiraGTx in the third quarter worth about $1,636,000. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Price Performance

Shares of NASDAQ:MGTX opened at $7.50 on Wednesday. The company’s fifty day moving average is $6.59 and its two-hundred day moving average is $5.88. The company has a market cap of $586.15 million, a P/E ratio of -6.20, a price-to-earnings-growth ratio of 0.37 and a beta of 1.23. MeiraGTx Holdings plc has a 12-month low of $3.85 and a 12-month high of $8.75. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.

MeiraGTx (NASDAQ:MGTX) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). The company had revenue of $21.39 million during the quarter, compared to analysts’ expectations of $1.50 million. MeiraGTx had a negative return on equity of 146.38% and a negative net margin of 633.05%. Equities analysts expect that MeiraGTx Holdings plc will post -1.48 earnings per share for the current fiscal year.

Insider Buying and Selling at MeiraGTx

In related news, CFO Richard Giroux sold 24,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.29, for a total value of $150,960.00. Following the completion of the sale, the chief financial officer now directly owns 849,947 shares in the company, valued at approximately $5,346,166.63. This represents a 2.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Alexandria Forbes sold 35,839 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total transaction of $231,878.33. Following the transaction, the chief executive officer now directly owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.40% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on MGTX. Chardan Capital reissued a “buy” rating and set a $36.00 target price on shares of MeiraGTx in a research note on Monday, February 24th. Royal Bank of Canada upped their price target on MeiraGTx from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Monday.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.